Estimation of mortality rate and disproportionality analysis of anaphylactic reactions following COVID-19 vaccination

ABSTRACT

The emergency use authorization for the coronavirus disease 2019(COVID-19) vaccine has risen up expectations and concerns. Post market surveillance plays key role in assessing the benefit and risks. Our study aimed to estimate the death rate and analyze the disproportionality of anaphylactic reactions after receiving the COVID-19 vaccine.Data was gathered from the Vaccine Adverse Event Reporting system (VAERS) public data releases.To determine the mortality rate and anaphylactic reactions linked to COVID-19 vaccine provided between December 20, 2020 and June 24, 2022, a thorough study was conducted. Individuals who were 18 years of age or older and had received the COVID vaccines compared with other vaccine of same age group were included. Age, gender, onset of interval and days in hospital has been considered in assessing death rate. By comparing reports of anaphylactic reactions following the COVID-19 vaccines to all other vaccines using the Evans criteria, a disproportional analysis is performed using Proportional Reporting Ratio (PRR).However, ongoing surveillance of older adults who have received vaccinations is necessary. With regard to an anaphylactic reaction linked to the COVID-19 vaccination, no potential signal was observed.To systematically validate the information provided by VAERS, additional epidemiologic investigations are required.